TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04864145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
Study: NCT06109610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
Study: NCT05889689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Smarts Plus & Mind Matters
Description: 18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Smarts Plus alone
Description: 14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preparing Adolescents for Young Adulthood (PAYA).
Description: A financial literacy curriculum
Study: NCT06265324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
Study: NCT05406336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm
Description: The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
Study: NCT06020248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wear clothing that has been exposed to cigarette smoke for 3 hours.
Description: Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wear clothing that has been exposed to cigarette smoke for 3 hours.
Description: Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
Study: NCT05428280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy technique
Description: Muscle Energy Technique (MET) is a technique that was developed in 1948 by Fred Mitchell, Sr, D.O\[1\]. It is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofacial mobilization
Description: It is a type of gentle, constant massage that releases tightness and pain throughout your myofascial tissues
Study: NCT04740723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRF System Renal Denervation
Description: The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery
Study: NCT05488288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh repair
Description: Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture repair
Description: The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
Study: NCT05323045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYON3521
Description: BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study: NCT05347862

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study.
Study: NCT04912154

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation protocol
Description: Rehabilitation protocol after open surgery for Achilles tendon rupture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: Rehabilitation protocol after open surgery for Achilles tendon rupture
Study: NCT04545528

Intervention type: BEHAVIORAL
Intervention: Dietary recommendations
Description: The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
Study: NCT04952480

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-escalated adaptive radiotherapy
Description: Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent standard of care platinum doublet based therapy
Study: NCT06164015

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound scan with power Doppler angiography
Description: The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound scan with power Doppler angiography
Description: The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
Study: NCT06270277

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Description: Questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Description: Questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Strengths and Difficulties Questionnaire (SDQ)
Description: Questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Strengths and Difficulties Questionnaire (SDQ)
Description: Questionnaire
Study: NCT04721366

Intervention type: OTHER
Intervention: Standard of Care
Description: Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
Study: NCT05885776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrrolidine、trastuzumab、AI
Description: Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
Study: NCT05366296

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A Lyophilized COVID-19 mRNA Vaccine
Description: Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide), DSPC \[1,2- distearoyl-sn-glycero-3-phosphocholine\], Cholesterol, Trometamol and Sucrose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride solution
Study: NCT05693025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
Study: NCT06495593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Standard ocrelizumab dosing
Study: NCT05459558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice 1
Description: 5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Dentifrice 2
Description: 5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice
Description: Regular Fluoride Dentifrice.
Study: NCT04750278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 100 mg
Description: FP-025 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 300 mg
Description: FP-025 300 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT05205629

Intervention type: DRUG
Intervention: Donafenib combined with TACE
Description: Donafenib(200mg bid po) combined with TACE
Study: NCT05559632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osteotomy for implant placement
Description: preparing the bone for implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotomy for implant placement
Description: preparing the bone for implant placement
Study: NCT04666363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil
Description: the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
Study: NCT06544369

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccin
Description: injection

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccin
Description: injection
Study: NCT04831996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study: NCT03747718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
Study: NCT06133959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The-Optimal-Lymph-Flow (TOLF) Program
Description: TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The-Optimal-Lymph-Flow (TOLF) Program
Description: TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
Study: NCT05565885

Intervention type: OTHER
Intervention: Sampling
Description: 4 blood sampling per patient and an additional one in case of relapse
Study: NCT05750836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific nursing support
Description: * 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-specific nursing support
Description: Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
Study: NCT04947514

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo (topical saline)
Description: The untreated breast will receive topical saline.
Study: NCT03995797

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser therapy
Description: Erbium YAG laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Erbium YAG laser
Study: NCT05006326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study: NCT05730309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized discharge and expedited referral instructions
Description: The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
Study: NCT04554745

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of pregnant women

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of pregnant women
Study: NCT05891145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
Study: NCT05336175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
Study: NCT06243237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture(Superficial Acupuncture)
Description: Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
Study: NCT05482191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses~* Diet and exercise instruction by professional nutritionist using internet applet~* Take part in sports activities that are organized by the sports health teacher during school hours.